Skip to Content
Morningstar

Curaleaf Delays Fourth-Quarter and Fiscal-Year 2022 Earnings Release

""
Securities In This Article
Curaleaf Holdings Inc
(CURA)

Curaleaf’s CURA fourth-quarter and full-year 2022 earnings release was originally set for March 28. On March 24, the company announced a delay until some date in April, yet to be announced. The company cited complexities with converting to U.S. GAAP from IFRS reporting standards as the main reason for the delay.

For now, our fair value estimates of $25 and CAD 34 per share are unchanged for no-moat Curaleaf. However, we will wait for Curaleaf’s full release for a complete understanding and any potential changes.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Kristoffer Inton

Strategist
More from Author

Kristoffer Inton is an equity strategist, ESG, for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. He covers cannabis companies.

Before joining Morningstar in 2013, Inton was an investment banking associate for Guggenheim Securities in New York. Previously, he was an investment banking analyst for Merrill Lynch in Chicago and New York.

Inton holds a bachelor's degree in finance with high honors from the University of Illinois and a Master of Business Administration with distinction from Northwestern University's Kellogg School of Management.

Sponsor Center